GlobeNewswire by notified

SMISS launched its electronic vapor gadgets technology platform TempSure™, the world's 1st cannabis vape hardware featuring intelligent duplex communication

Share

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

SHENZHEN, China, Nov. 29, 2023 (GLOBE NEWSWIRE) -- As one of the largest exhibitions in the global cannabis industry, the MJBizCon 2023 CBD/THC/Cannabis Expo opened in Las Vegas as scheduled. On November 29th local time, SMISS officially launched the World's 1st Cannabis Vape Hardware Featuring Intelligent Duplex Communication, TempSure™ at the event. The platform utilizes advanced technology to provide users with the best intelligent vaporization experience. The name TempSure™ implies precise vaporization temperature control, offering users the perfect CBD vaporization experience.

TempSure™ has developed an intelligent MCU control chip and a proprietary PID dynamic compensation technology solution. By accurately monitoring the heating state of CeramicMesh™ coil vaporization (oil conductivity, oil temperature, and smoke signal), it dynamically adjusts the optimal power energy output to achieve accurate heating temperature control for scientific vaporization. This enables users to experience the ultimate vaping taste and deliver a perfect smoke sensation.

The TempSure™ technology solution offers eight breakthrough experiences:

  1. The World's 1st Intelligent Duplex Communication Technology, Designed for CBD, THC, and Alternative Cannabinoids. 
  2. Covering a wide heating temperature, and temperature control with 10 levels of adjustment. 
  3. Reduce the production of harmful substances such as Aldehydes, the best eco-friendly and harm-reducing health choice. 
  4. CeramicMesh™ heating coil, ultra heating efficiency, and stable performance 
  5. 25w instant vapor production, get relief in 0.005s 
  6. PID dynamic compensation algorithm, TPM increased 67%, consistent flavor, consistent vapor production. 
  7. Anti-Burn Protection Technology, No Worrying About Burnt Taste 
  8. Adjustable power-pinpoint the power needed for different oil types

The TempSure™ vaporization technology solution has three core leading advantages: Fast smoke generation, No smoke attenuation and Anti-burn protection. At the same time, accurate temperature control is also crucial for reducing the harmful ingredients such as the low molecular organic compounds. TempSure™ achieves this by scientifically and accurately controlling the vaporization temperature, significantly reducing the emission of harmful aldehydes and ketones compared to others. This makes TempSure™ a safer and healthier choice for all cannabis vapers.

At the Expo, SMISS also released four products by using TempSure platform technology, they are pink CLOUD POUCH, blue BOOST, green MELLOW and CRYSTAL CUBE. They all have visible oil reservoirs and real-time power consumption digital screens.

TempSure™ vaporization technology solution features three benefits that sets apart from the competition: instant and powerful vapor production, superior consistent taste, and anti-burn+ product shortage protection. Leap into a new era of cannabis vaping with TempSure™.

ABOUT SMISS

SMISS Technology Co., Ltd is the world's leading provider of e-cigarette solutions and equipment manufacturing services. Encompassing the fields of atomizer coil technology, ENDs, CBD/THC, IMV, HNB, dry herbal product equipment, tobacco heating technology, E-liquid, etc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/123d7720-4470-46a9-8d33-f7b48cb4bed3

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria24.2.2024 15:51:43 CET | Press release

Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipeline Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These r

Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release

Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of​ the delisting ​procedure and ​consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

HiddenA line styled icon from Orion Icon Library.Eye